Ursodeoxycholic acid in cystic fibrosis-associated liver disease

被引：7
|
作者：
Ooi, Chee Y. [1 ,2 ,3 ]
Nightingale, Scott [4 ]
Durie, Peter R. [5 ,6 ,7 ]
Freedman, Steven D. [8 ,9 ]
机构：
[1] Sydney Childrens Hosp, Dept Gastroenterol, Sydney, NSW, Australia
[2] Sydney Childrens Hosp, Cyst Fibrosis Clin, Sydney, NSW, Australia
[3] Univ New S Wales, Fac Med, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia
[4] Univ Newcastle, Discipline Paediat & Child Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia
[5] Hosp Sick Children, Res Inst, Toronto, ON, Canada
[6] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON, Canada
[7] Univ Toronto, Toronto, ON M5S 1A1, Canada
[8] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[9] Harvard Univ, Sch Med, Boston, MA USA
来源：
JOURNAL OF CYSTIC FIBROSIS | 2012年 / 11卷 / 01期
关键词：
Liver disease; Cystic fibrosis; Cirrhosis; Portal hypertension; Ursodeoxycholic acid; ASYMPTOMATIC PATIENTS;
D O I：
10.1016/j.jcf.2011.08.002
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：72 / 73
页数：2
相关论文
共 50 条
  • [1] Ursodeoxycholic acid in cystic fibrosis-associated liver disease Response
    Colombo, Carla
    Debray, Dominique
    Kelly, Deirdre
    Houwen, Roderick
    Battezzati, Pier Maria
    Strandvik, Birgitta
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (01) : 74 - 75
  • [2] Ursodeoxycholic acid treatment in cystic fibrosis-associated liver disease
    Colombo, C
    Comi, S
    Moretti, E
    [J]. BIOLOGY OF BILE ACIDS IN HEALTH AND DISEASE, 2001, 120 : 311 - 316
  • [3] URSODEOXYCHOLIC ACID FOR CYSTIC FIBROSIS-ASSOCIATED LIVER-DISEASE - FINAL REPORT OF A MULTICENTER TRIAL
    COLOMBO, C
    PODDA, M
    BATTEZZATI, PM
    SANTINI, B
    IAPICHINO, L
    QUATTRUCCI, S
    LUCIDI, V
    FERRARI, R
    SCOTTA, S
    MINICUCCI, L
    CANDUSSO, M
    VALLETTA, E
    GAGLIARDINI, R
    SANTAMARIA, F
    BATTISTINI, F
    GIUNTA, A
    [J]. HEPATOLOGY, 1993, 18 (04) : A142 - A142
  • [4] Cystic fibrosis-associated liver disease
    Herrmann, Ulrike
    Dockter, Gerd
    Lammert, Frank
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2010, 24 (05) : 585 - 592
  • [5] Markers of cystic fibrosis-associated liver disease
    Narkewicz, MR
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2001, 32 (04): : 421 - 422
  • [6] Cystic fibrosis-associated liver disease in children
    Wasuwanich, Paul
    Karnsakul, Wikrom
    [J]. MINERVA PEDIATRICA, 2020, 72 (05) : 440 - 447
  • [7] Abnormalities in biliary drainage may predict a better response to ursodeoxycholic acid in cystic fibrosis-associated liver disease.
    Colombo, C
    Castellani, MR
    Crosignani, A
    Comi, S
    Giunta, A
    [J]. HEPATOLOGY, 1996, 24 (04) : 298 - 298
  • [8] A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease
    Lindblad, A
    Glaumann, H
    Strandvik, B
    [J]. HEPATOLOGY, 1998, 27 (01) : 166 - 174
  • [9] URSODEOXYCHOLIC ACID EFFECTS ON CYSTIC FIBROSIS LIVER DISEASE
    Ciuca, Ioana Mihaiela
    Pop, Liviu
    Ranetti, Aurelian Emil
    Popescu, Iuliana M.
    Almajan-Guta, Bogdan
    Malita, Ioana Maria
    Anghel, Ion
    [J]. FARMACIA, 2015, 63 (04) : 543 - 547
  • [10] Transcriptional Basis for Hepatic Fibrosis in Cystic Fibrosis-associated Liver Disease
    Pereira, Tamara N.
    Lewindon, Peter J.
    Greer, Ristan M.
    Hoskins, Anita C.
    Williamson, Richard M.
    Shepherd, Ross W.
    Ramm, Grant A.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2012, 54 (03): : 328 - 335
12345